Panel Gives Blessing for Pfizer’s Lorlatinib, Astellas AML Drug; Approval Expected in September

A key health ministry panel on August 29 backed approval for a batch of drugs including Pfizer’s next-generation ALK inhibitor lorlatinib and Astellas Pharma’s acute myeloid leukemia (AML) treatment gilteritinib. If all goes without a hitch, they will be officially...read more